vs
Side-by-side financial comparison of COLONY BANKCORP INC (CBAN) and Sight Sciences, Inc. (SGHT). Click either name above to swap in a different company.
COLONY BANKCORP INC is the larger business by last-quarter revenue ($39.9M vs $20.4M, roughly 2.0× Sight Sciences, Inc.). COLONY BANKCORP INC runs the higher net margin — 20.6% vs -20.4%, a 41.0% gap on every dollar of revenue. Over the past eight quarters, COLONY BANKCORP INC's revenue compounded faster (19.6% CAGR vs 2.9%).
Colony Bankcorp Inc is a US-based bank holding company that operates Colony Bank. It provides a full suite of personal and commercial banking services including deposit accounts, consumer and business loans, mortgage services, and wealth management solutions, primarily serving retail customers and small-to-medium enterprises across the state of Georgia.
Sight Sciences, Inc. is a commercial-stage medical technology company focused on developing and commercializing innovative products for treating common eye conditions including glaucoma and dry eye disease. It offers minimally invasive surgical devices and non-surgical care solutions, primarily serving ophthalmology clinicians and patients across the United States.
CBAN vs SGHT — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $39.9M | $20.4M |
| Net Profit | $8.2M | $-4.2M |
| Gross Margin | — | 87.3% |
| Operating Margin | — | -18.0% |
| Net Margin | 20.6% | -20.4% |
| Revenue YoY | — | 6.9% |
| Net Profit YoY | 24.1% | 64.9% |
| EPS (diluted) | — | $-0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $39.9M | — | ||
| Q4 25 | $36.9M | $20.4M | ||
| Q3 25 | $32.8M | $19.9M | ||
| Q2 25 | $32.5M | $19.6M | ||
| Q1 25 | $30.0M | $17.5M | ||
| Q4 24 | $30.8M | $19.1M | ||
| Q3 24 | $28.6M | $20.2M | ||
| Q2 24 | $27.9M | $21.4M |
| Q1 26 | $8.2M | — | ||
| Q4 25 | — | $-4.2M | ||
| Q3 25 | $5.8M | $-8.2M | ||
| Q2 25 | $8.0M | $-11.9M | ||
| Q1 25 | $6.6M | $-14.2M | ||
| Q4 24 | — | $-11.8M | ||
| Q3 24 | $5.6M | $-11.1M | ||
| Q2 24 | $5.5M | $-12.3M |
| Q1 26 | — | — | ||
| Q4 25 | — | 87.3% | ||
| Q3 25 | — | 86.4% | ||
| Q2 25 | — | 84.8% | ||
| Q1 25 | — | 86.2% | ||
| Q4 24 | — | 86.8% | ||
| Q3 24 | — | 83.9% | ||
| Q2 24 | — | 85.8% |
| Q1 26 | — | — | ||
| Q4 25 | 25.9% | -18.0% | ||
| Q3 25 | 22.2% | -39.7% | ||
| Q2 25 | 30.9% | -59.6% | ||
| Q1 25 | 27.6% | -79.2% | ||
| Q4 24 | 28.8% | -62.5% | ||
| Q3 24 | 24.6% | -55.7% | ||
| Q2 24 | 24.8% | -59.2% |
| Q1 26 | 20.6% | — | ||
| Q4 25 | — | -20.4% | ||
| Q3 25 | 17.7% | -41.0% | ||
| Q2 25 | 24.6% | -61.0% | ||
| Q1 25 | 22.0% | -80.8% | ||
| Q4 24 | — | -62.1% | ||
| Q3 24 | 19.7% | -54.9% | ||
| Q2 24 | 19.6% | -57.7% |
| Q1 26 | — | — | ||
| Q4 25 | $0.42 | $-0.07 | ||
| Q3 25 | $0.33 | $-0.16 | ||
| Q2 25 | $0.46 | $-0.23 | ||
| Q1 25 | $0.38 | $-0.28 | ||
| Q4 24 | $0.43 | $-0.23 | ||
| Q3 24 | $0.32 | $-0.22 | ||
| Q2 24 | $0.31 | $-0.25 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $295.8M | $92.0M |
| Total DebtLower is stronger | — | $42.4M |
| Stockholders' EquityBook value | $380.4M | $63.9M |
| Total Assets | $3.7B | $115.3M |
| Debt / EquityLower = less leverage | — | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $295.8M | — | ||
| Q4 25 | — | $92.0M | ||
| Q3 25 | — | $92.4M | ||
| Q2 25 | — | $101.5M | ||
| Q1 25 | — | $108.8M | ||
| Q4 24 | — | $120.4M | ||
| Q3 24 | — | $118.6M | ||
| Q2 24 | — | $118.2M |
| Q1 26 | — | — | ||
| Q4 25 | $258.1M | $42.4M | ||
| Q3 25 | — | $42.4M | ||
| Q2 25 | — | $42.4M | ||
| Q1 25 | — | $42.4M | ||
| Q4 24 | $248.0M | $40.0M | ||
| Q3 24 | — | $37.1M | ||
| Q2 24 | — | $35.0M |
| Q1 26 | $380.4M | — | ||
| Q4 25 | $375.9M | $63.9M | ||
| Q3 25 | $302.3M | $64.3M | ||
| Q2 25 | $293.9M | $70.0M | ||
| Q1 25 | $286.9M | $77.6M | ||
| Q4 24 | $278.7M | $87.5M | ||
| Q3 24 | $276.1M | $95.0M | ||
| Q2 24 | $264.7M | $101.6M |
| Q1 26 | $3.7B | — | ||
| Q4 25 | $3.7B | $115.3M | ||
| Q3 25 | $3.2B | $116.3M | ||
| Q2 25 | $3.1B | $122.0M | ||
| Q1 25 | $3.2B | $129.7M | ||
| Q4 24 | $3.1B | $142.8M | ||
| Q3 24 | $3.1B | $143.6M | ||
| Q2 24 | $3.0B | $149.7M |
| Q1 26 | — | — | ||
| Q4 25 | 0.69× | 0.66× | ||
| Q3 25 | — | 0.66× | ||
| Q2 25 | — | 0.61× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | 0.89× | 0.46× | ||
| Q3 24 | — | 0.39× | ||
| Q2 24 | — | 0.34× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-1.8M |
| Free Cash FlowOCF − Capex | — | $-2.0M |
| FCF MarginFCF / Revenue | — | -9.7% |
| Capex IntensityCapex / Revenue | — | 0.8% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-5.5M | $-1.8M | ||
| Q3 25 | $14.4M | $-8.7M | ||
| Q2 25 | $15.8M | $-7.5M | ||
| Q1 25 | $17.9M | $-11.6M | ||
| Q4 24 | $23.4M | $-3.5M | ||
| Q3 24 | $20.5M | $362.0K | ||
| Q2 24 | $1.1M | $-9.5M |
| Q1 26 | — | — | ||
| Q4 25 | $-6.9M | $-2.0M | ||
| Q3 25 | $14.1M | $-8.9M | ||
| Q2 25 | $15.8M | $-7.8M | ||
| Q1 25 | $17.6M | — | ||
| Q4 24 | $22.3M | $-3.6M | ||
| Q3 24 | $20.2M | $311.0K | ||
| Q2 24 | $990.0K | $-9.5M |
| Q1 26 | — | — | ||
| Q4 25 | -18.7% | -9.7% | ||
| Q3 25 | 42.9% | -44.7% | ||
| Q2 25 | 48.5% | -39.6% | ||
| Q1 25 | 58.7% | — | ||
| Q4 24 | 72.5% | -18.9% | ||
| Q3 24 | 70.6% | 1.5% | ||
| Q2 24 | 3.5% | -44.7% |
| Q1 26 | — | — | ||
| Q4 25 | 3.7% | 0.8% | ||
| Q3 25 | 1.1% | 0.9% | ||
| Q2 25 | 0.3% | 1.1% | ||
| Q1 25 | 1.2% | 0.0% | ||
| Q4 24 | 3.5% | 0.7% | ||
| Q3 24 | 1.0% | 0.3% | ||
| Q2 24 | 0.5% | 0.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 2.48× | — | ||
| Q2 25 | 1.99× | — | ||
| Q1 25 | 2.71× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.64× | — | ||
| Q2 24 | 0.20× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CBAN
| Net Interest Income | $29.2M | 73% |
| Noninterest Income | $10.7M | 27% |
SGHT
| Surgical Glaucoma | $19.7M | 96% |
| Other | $724.0K | 4% |
